Trial Profile
A 2-part, Randomized, Double-blind, Placebo-controlled, Sequential Group, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG2737 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2018
Price :
$35
*
At a glance
- Drugs GLPG 2737 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Galapagos NV
- 01 Dec 2016 New trial record
- 28 Nov 2016 According to a Galapagos NV media release, top-line results are expected in the second quarter of 2017.